Clinical Trials Arena on MSN
VectorY doses first participant in Phase I/II PIONEER-ALS trial
The study aims to enrol 12 adults with ALS at locations in Europe, the UK and US.
The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.
Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311 Patients with recurrent H&N Ca ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results